2025-04-04 20:37:22
Latest Post
Sai Life Sciences sets up Peptide Research Center in India
Netweb Technologies Ltd receives PLI Incentive Under IT Hardware Scheme 2.0
BHEL signs contract for ± 800 kV, 6000 MW Bhadla-Fatehpur LCC HVDC Terminal Station along with AC Transmission at Bhadla and Fatehpur
DEE Development Engineers Limited receives order worth approx. Rs. 55 crores- SURATWWALA BUSINESS GROUP Ltd purchases new commercial office space
Stock Report
Gujarat Themis Biosyn Ltd posts net profit of Rs. 11.69 crores in Q4FY23
Posted On : 2023-05-13 22:41:51( TIMEZONE : IST )
GUJARAT THEMIS BIOSYN LTD. has reported Standalone financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 29.5712 crores during the period ended March 31, 2023 as compared to Rs. 29.9713 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 11.6922 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 9.8074 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 8.05 for the period ended March 31, 2023 as compared to Rs. 6.75 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹29.5712 crs | ₹29.9713 crs |  -1.33% |
| Net Profit | ₹11.6922 crs | ₹9.8074 crs |  19.22% |
| EPS | ₹8.05 | ₹6.75 | 19.26% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.29.5712 crores during the period ended March 31, 2023 as compared to Rs.30.2724 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.11.6922 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.9.7888 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.8.05 for the period ended March 31, 2023 as compared to Rs.6.74 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹29.5712 crs | ₹30.2724 crs | -2.32% |
| Net Profit | ₹11.6922 crs | ₹9.7888 crs | 19.44% |
| EPS | ₹8.05 | ₹6.74 | 19.44% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.154.9967 crores during the Financial Year ended March 31, 2023 as compared to Rs.118.9040 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.57.9688 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.43.6242 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.39.90 for the Financial Year ended March 31, 2023 as compared to Rs.30.03 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹154.9967 crs | ₹118.9040 crs | 30.35% |
| Net Profit | ₹57.9688 crs | ₹43.6242 crs | 32.88% |
| EPS | ₹39.90 | ₹30.03 | 32.87% |
Shares of GUJARAT THEMIS BIOSYN LTD. was last trading in BSE at Rs. 798.10 as compared to the previous close of Rs. 813.40. The total number of shares traded during the day was 13826 in over 544 trades.
The stock hit an intraday high of Rs. 824.80 and intraday low of 792.25. The net turnover during the day was Rs. 11212643.00.
